Form 4: BioAge Labs Director Reports Conversion of Preferred Stock and Acquisition of Common Stock

Director Vijay Satyanand Pande reports the conversion of preferred stock to common stock and acquisition of common stock through various entities following BioAge Labs' initial public offering.

Summary

• On September 27, 2024, Vijay Satyanand Pande, a director of BioAge Labs, filed a Form 4 detailing changes in beneficial ownership of the company's securities.
• The filing reports the conversion of Series A-1, Series B, Series C, and Series D preferred stock into common stock at a ratio of 1-for-0.224084614 upon the closing of BioAge Labs' initial public offering (IPO).
• Pande also reported the acquisition of 900,000 shares of common stock at a price of $18 per share through Andreessen Horowitz LSV Fund III, L.P.
• The reported securities are indirectly held through various AH Bio Funds and Andreessen Horowitz funds, with Pande disclaiming beneficial ownership except to the extent of his pecuniary interest.
• The filing clarifies the relationships between the various AH Funds and their general partners, noting that Marc Andreessen and Ben Horowitz may be deemed to share voting and investment discretion.

Sentiment

Score: 7

Explanation: The document reflects standard post-IPO transactions and insider activity, suggesting a neutral to slightly positive sentiment due to continued investment by Andreessen Horowitz.

Positives

• The conversion of preferred stock to common stock simplifies the company's capital structure following the IPO.
• The acquisition of 900,000 shares at $18 per share demonstrates continued investment in BioAge Labs by Andreessen Horowitz.
• The filing provides transparency regarding the ownership structure and relationships between various investment funds and their general partners.

Risks

• Pande disclaims beneficial ownership of the securities held by the AH Funds, which could indicate a limited direct influence on the company's decisions.
• The complex ownership structure involving multiple funds and general partners could create potential conflicts of interest.

Future Outlook

The document does not contain specific forward-looking statements, but the conversion of preferred stock and acquisition of common stock suggest ongoing confidence in BioAge Labs' future prospects following its IPO.

Industry Context

Form 4 filings are standard practice for company insiders and large shareholders, providing transparency into their transactions and ownership positions. This filing reflects activity following BioAge Labs' IPO, which is a significant event for the company and its investors.

Comparison to Industry Standards

• Form 4 filings are a regulatory requirement for insiders of publicly traded companies in the US, ensuring transparency in their trading activities.
• The conversion of preferred stock to common stock upon an IPO is a common practice, simplifying the capital structure and aligning the interests of preferred and common shareholders.
• The involvement of venture capital firms like Andreessen Horowitz is typical for biotech companies, providing funding and expertise to support their growth.

Stakeholder Impact

• Shareholders will see a simplified capital structure with the conversion of preferred stock to common stock.
• The continued investment by Andreessen Horowitz may boost investor confidence.

Key Dates